Academic Center for Thyroid Diseases

Last updated: 242 days ago.

The major focus is complex Thyroid Diseases that require multidisciplinary care.
The goal of the Academic Center for Thyroid Diseases is to improve current treatments and to develop new therapies for patients with commonand rare thyroid diseases through a better understanding of these diseases, and thereby maintain and expand the national and international leading position of Erasmus MC as a tertiary referral center for complex thyroid diseases. The center is organized around three standardized multidisciplinary clinical pathways, with separate multidisciplinary teams that are all closely linked to different lines of research.

Academic Center of Excellence

Research Activities

The research lines of the ACE are organized in three knowledge centers, closely linked to the three multidisciplinary clinical pathways. Please find below a few examples illustrating the multidisciplinary international research:

1. (Suspicion of) Thyroid Cancer: Currently a multicenter study is being performed to assess the possible early identification of patients with permanent hypoparathyroidism after a total or completion thyroidectomy (Surgery, Clinical chemistry, endocrinology). These studies are coordinated by PhD students shared between Dept's of Internal Medicine and Surgery.

2. Graves' disease and Graves' ophtalmopathy: The ACE identified PDGF as a key factor in the pathogenesis of graves' ophthalmopathy and showed that drugs targeting this growth factor have beneficial effects on cultured orbital fibroblasts collected from patients with severe Graves' ophtalmopathy (departments: immunology, endocrinology, ophthalmology). A collaborative clinical trial has been performed by the Divisions of Immunology and Endocrinology in collaboration with the Rotterdam Eye Hospital.

3. Thyroid hormone signaling disorders: The ACE identified one of the first patients with a novel clinical syndrome due to a defective thyroid hormone receptor (van Mullem, NEJM, 2012) and is currently unraveling this clinical syndrome. The index patient was referred from Greece, illustrating the international position of the ACE. Recently, a new form of thyroid hormone transporter deficiency was discovered, again through an international referral (Stromme et al, Thyroid 2018). Previously, the ACE identified another syndrome due to defects in thyroid hormone transport (Friesema, Lancet, 2004). The ACE established a worldwide consortium on this disorder to uniformly document the disease characteristics to inform clinical management (Groeneweg et al, Lancet Diabetes and Endocrinology, 2020). The ACE is led the first clinical trial (multicenter, international) for treatment of this disease (departments: (pediatric) endocrinology, clinical chemistry, genetics) (Groeneweg et al, Lancet Diabetes and Endocrinology, 2019) and leads the second international clinical trial in this niche field.  Finally, two new key players in thyroid hormone signaling have been identified through an international collaboration and close interaction between epidemiology and molecular biology research (Teumer et al, Nat Comm, 2018).

Type of


- Initiation of a collaborative multidisciplinary regional network for patients with thyroid disease. In this network, specialists from 11 hospitals in South-West Netherlands have standardized care and collaborate scientifically ( Goal of this network of 11 hospitals is to optimize care and collaborate between hospitals in such a way that the ACE can focus on her role as tertiary care provider on one hand, but patients with non-tertiary diseases can still be included in clinical trials and biobanking efforts. See for a video explanation. In 2016, a joint PhD student of the network has started several research projects, in which patients from all 11 hospitals are being included. Currently, we are exploring the extension of the network with a second Academic Hospital and its affiliated hospitals.

- Initiation of a Consortium on Thyroid Function and Pregnancy (more than 23 centers, including more than 80,000 mother-child pairs). In part funded by an NWO Replication Grant. Multiple research projects are currently ongoing, lead by different institutes.

- Initiation and coordination of investigator-initiated international multi-center phase 2 clinical trial with T3 analog Triac for MCT8 deficiency (9 countries, EU and non-eU).

- Initiation of a novel clinical trial for Graves eye disease (endocrinology, immunology, ophthalmology), joint collaboration with Rotterdam Eye Hospital (NTR6579)

- Initiation of new clinical trial for transporter defect (NCT02396459), lead by the ACE, under the umbrella of the European Reference Network (ERN) for rare endocrine diseases (ENDO-ERN); The ACE is chairing the Thyroid Main Thematic group of this ERN; start discussions with relevant authorities considering design of the trial (EMA)

- Collaboration with ACE-ENCORE: effect of thyroid hormone on iPSCs differentiated into neural networks

-Coordination of a large international consortium on MCT8 deficiency (> 20 countries)

- The ACE identified one of the first patients with a novel clinical syndrome due to a defective thyroid hormone receptor (van Mullem, NEJM, 2012) and is currently further unraveling this clinical syndrome. The index patient was referred from Greece, illustrating the international position of the ACE. Fifteen years after the identification of the first thyroid hormone transporter deficiency, the ACE recently identified a second disorder due to another transporter defect (patient from Norway).



The ACE is heavily involved and well-evaluated (SET Q, D-RECT) in education at Erasmus MC (Bachelor, Master, PhD students, clinical training for medical specialists, postgraduate courses and facultative courses).
Fifteen PhD students are involved in the basic, translational and clinical research of the ACE.

Annually, we have 1-2 international visiting fellows. Specific teaching activities:

Within Erasmus MC:

  • Coordination Bachelor Theme 1.C.13, participation in Bachelor Clinical Technology.
  • Clinical skills training and journal clubs.
  • Active participation in Master 1.B3
  • Keuzeonderwijs: "Inflammation, paradise or evil empire" & "MINOR Endocrinology"
  • Clinical Reasoning training of Master 1B
  • Organization of post-graduate MolMed course "Basic and Translational Endocrinology"
  • Training team (opleidingsteam) of the Division of Endocrinology Regional/national:




· Bi-annual regional symposium on thyroid disease, attended by >125 internists, surgeons, radiologists, pathologists, and nuclear medicine physicians.

· Annual "KNAW" symposium of the Dutch Thyroid Club

· Medical Advisory Board of the Patient Organization SON

· Annual patient information evenings

· Educational Course for General Practitioners.



  • Educational Board of the European Thyroid Association
  • Iodine Global Network, which aims to eliminate global iodine deficiency together with partners including UNICEF and WHO.
  • Program organizing committee of the European & American Endocrine Society and European & American Thyroid Association
  • Active participation in different international guideline committees


2015- present: Regular newsletter on MCT8 deficiency, disseminated to patients, parents, researchers and health care professionals.

2017: Organization of a symposium on thyroid diseases (159 registered participants, in collaboration with 10 regional partner hospitals (www.schildkliernetwerk), a symposium on Thyroid and Pregnancy (132 registered participants, joint organization between depts. Internal medicine, obstetrics and gynecology and epidemiology), and an International Workshop on Thyroid Hormone and Aging (invitation only, 29 participants)

2017: Contribution medical and scientific information to AHDS-MCT8 patient foundation (

2017: Webinar on MCT8 deficiency for parents (supported by EuRordis)

2018: Organization of an International Workshop on Resistance to Thyroid Hormone (109 participants from 4 continents), and the first national symposium of the Dutch Thyroid Cancer Group (500 registrations)

2019: Organization of a symposium on thyroid diseases (150 registered participants, in collaboration with 10 regional partner hospitals (www.schildkliernetwerk),


Care Activities

• Patient care in the Rotterdam Thyroid Center is organized around three standardized multidisciplinary clinical pathways, in which all different specialties collaborate on a daily basis for optimal care of patients with complex thyroid diseases: The three clinical care pathways are:
1) (Suspicion of) Thyroid cancer
2) Therapy resistant Graves' disease and Graves' ophtalmopathy
3) Thyroid Hormone Signaling Disorders

• To develop better markers to predict the effect of current treatments, as well as to develop new therapies, almost all patients in the Rotterdam Thyroid Center are asked for permission to use their clinical data and/or material for clinical research. Where appropriate, patients are asked for inclusion in EuRRECa (European Registries for Rare Endocrine Conditions), which is linked to Endo-ERN (see below).

• The Academic Center is an integral part of the NFU-approved expertise center "Rare Endocrine Diseases". In addition, the Academic Center plays a significant role in Endo-ERN (European Reference Network on rare endocrine conditions), as the European ERN-coordinator for thyroid disease and a Steering Committee member of the ERN for Rare Endocrine Disorders. All care in the Academic Center is organized around standardized multidisciplinary clinical care pathways, and almost only involves academic care. The multidisciplinary approach for thyroid cancer, leading to a reduction in lead time of more than 50%, was awarded a stipend from Erasmus MC zorgpaden-II.

• As illustrated by the international referral of patients and international consultation function, the Academic Center is a world leading center for complex thyroid diseases. This is also illustrated by the international awards, invited lectures, and active participation in National and International Guidelines of different members of the Academic Center.

• To accommodate patient needs, there is a close collaboration of the Academic Center with the Patient Organisation "Schildklier Organisaties Nederland", leading to joint patient information meetings, brochures, and even clinical research financed by the patient organization.

• An international patient registry was launched for MCT8 deficiency (website Aggregate data will be shared with patient organization and representatives. 

Societal Relevance to Research, Education and Patient Care

The Academic Center for Thyroid Diseases has contributed to the understanding and management of different thyroid disorders, ranging from the identification of rare and severe thyroid hormone signaling disorders towards causing a paradigm shift for the treatment of thyroid dysfunction during pregnancy. Research generated by the ACE has influenced various (inter)national guidelines (CBO, European and American Thyroid Association). Research has gained attention in various media ((international) newspapers, television, national radio, magazines of patient organisations, etc). Members of the ACE closely collaborate with diverse national and international patient organisations, which is well recognized by these groups.

To strengthen the role as a European Educational Center for Thyroid diseases, two members of the ACE have initiated an annual basic course and an annual clinical course in thyroidology via the Educational Committee of the European Thyroid Association.

A member of the ACE is National representative for the Netherlands of the Iodine Global Network, which aims to eliminate global iodine deficiency by working closely with partners (including UNICEF and WHO) and national governments. Furthermore, the ACE actively participates in the Scientific Advisory Board of the World Iodine Association and the Steering Committee of the EU-funded EUthyroid project, which aims to eliminate iodine deficiency in Europe.

Viability of Research, Education and Patient Care

Knowledge sharing is organized via weekly meetings during which basic scientists, PhD students, research physicians and clinicians discuss basic, translational and clinical studies. In addition, there are regular meetings of individual researchers (PhDs, post-docs) with PIs. All PhD's participate in weekly research seminars of the Dept of Endocrinology. Various members of the ACE have worked abroad at top-ranking institutes (National Institutes of Health, Bethesda, USA; Harvard Medical School and/or Harvard School of Public Health, Boston, USA; Cambridge University, UK).

All members of the ACE are regularly invited speakers of various international conferences, and have received multiple international prestigious prizes. Talented PhD students are stimulated to work internationally and start own independent research lines. In the last four years, four former PhD students have done a post-doctoral research fellowship in Cambridge or Boston, financed with personal grants (including Marie-Curie & Fulbright Scholarships). Members of the ACE have received 18 international prizes at international meetings in the last 5 years, and PhD students of the ACE have received 38 travel grants in the last 5 years.

Valorization of current research on a novel treatment for patients with a thyroid hormone transporter defect (contract negotiations assisted by TTO) (NCT02060474). 

Active Twitter account (Rdam Thyroid Center)

2017: >1.7 Million Euros of funding (NWO, ZonMW, EUROSTARS, etc), 4 PhD defenses, first and last authorships in NEJM, Lancet, Nature Rev Endocrinology, Lancet Diabetes and Endocrinology, Circulation, JAMA Internal Medicine.

2018: > 1.2 Million EUros of funding (H2020, MRACE, VENI), 4PhD defenses, first and last authorships in Lancet Diabetes and Endocrinology, Nature Rev Endocrinology.

Key and relevant publications of the last five years

  • Groeneweg S, van Geest FS, Abacı A, Alcantud A, Ambegaonkar GP, Armour CM, Bakhtiani P, Barca D, Bertini ES, van Beynum IM, Brunetti-Pierri N, Bugiani M, Cappa M, Cappuccio G, Castellotti B, Castiglioni C, Chatterjee K, de Coo IFM, Coutant R, Craiu D, Crock P, DeGoede C, Demir K, Dica A, Dimitri P, Dolcetta-Capuzzo A, Dremmen MHG, Dubey R, Enderli A, Fairchild J, Gallichan J, George B, Gevers EF, Hackenberg A, Halász Z, Heinrich B, Huynh T, Kłosowska A, van der Knaap MS, van der Knoop MM, Konrad D, Koolen DA, Krude H, Lawson-Yuen A, Lebl J, Linder-Lucht M, Lorea CF, Lourenço CM, Lunsing RJ, Lyons G, Malikova J, Mancilla EE, McGowan A, Mericq V, Lora FM, Moran C, Müller KE, Oliver-Petit I, Paone L, Paul PG, Polak M, Porta F, Poswar FO, Reinauer C, Rozenkova K, Menevse TS, Simm P, Simon A, Singh Y, Spada M, van der Spek J, Stals MAM, Stoupa A, Subramanian GM, Tonduti D, Turan S, den Uil CA, Vanderniet J, van der Walt A, Wémeau JL, Wierzba J, de Wit MY, Wolf NI, Wurm M, Zibordi F, Zung A, Zwaveling-Soonawala N, Visser WE. Disease characteristics of MCT8 deficiency: an international, retrospective, multicentre cohort study. Lancet Diabetes Endocrinol. 2020 Jul;8(7):594-605.
  • Groeneweg S, Peeters RP, Moran C, Stoupa A, Auriol F, Tonduti D, Dica A, Paone L, Rozenkova K, Malikova J, van der Walt A, de Coo IFM, McGowan A, Lyons G, Aarsen FK, Barca D, van Beynum IM, van der Knoop MM, Jansen J, Manshande M, Lunsing RJ, Nowak S, den Uil CA, Zillikens MC, Visser FE, Vrijmoeth P, de Wit MCY, Wolf NI, Zandstra A, Ambegaonkar G, Singh Y, de Rijke YB, Medici M, Bertini ES, Depoorter S, Lebl J, Cappa M, De Meirleir L, Krude H, Craiu D, Zibordi F, Oliver Petit I, Polak M, Chatterjee K, Visser TJ, Visser WE. Effectiveness and safety of the tri-iodothyronine analogue Triac in children and adults with MCT8 deficiency: an international, single-arm, open-label, phase 2 trial. Lancet Diabetes Endocrinol. 2019 Sep;7(9):695-706.
  • A.A. van Mullem, D. Chrysis, A. Eythimiadou, E. Chroni, A. Tsatsoulis, Y.B. de Rijke, W.E. Visser, T.J. Visser, R.P. Peeters. Clinical phenotype of a new type of thyroid hormone resistance caused by a mutation of the TRα1 receptor; consequences of LT4 treatment. J Clin Endocrinol Metab. 2013 98:3029-38 (IF: 5,789) -> This is the first paper in the world on the treatment of patients with the novel clinical syndrome RTHa, and received the Endocrine Society Award for Outstanding Research published in J Clin Endocrinol Metab.
  • Effects of Chemical Chaperones on Thyroid Hormone Transport by MCT8 Mutants in Patient-Derived Fibroblasts. Groeneweg S, van den Berge A, Meima ME, Peeters RP, Visser TJ, Visser WE. Endocrinology. 2018 Mar 1;159(3):1290-1302. (IF: 3.961) -> This study shows an alternative approach to increase thyroid hormone uptake in cells of patients with MCT8 deficiency
  • S. Kersseboom, S. Horn, W.E. Visser, J. Chen, E.C. Friesema, C. Vaurs-Barrière, R.P. Peeters, H. Heuer, T.J. Visser. In vitro and mouse studies support therapeutic utility of triiodothyroacetic acid in MCT8 deficiency. Mol Endocrinol. 2014 28:1961-70 (IF: 4,022) -> This paper illustrates that TRIAC can restore thyroid hormone signalling in the brain in case of a transporter defect, and provided the basis for the current international multicenter Triac Trial NCT02060474, which was initiated and is lead by the ACE.
  • S. Virakul, J.W. Heutz, V.A. Dalm, R.P. Peeters, D. Paridaens, W.A. van den Bosch, N. Hirankarn, P.M. van Hagen, W.A. Dik. Basic FGF and PDGF-BB synergistically stimulate hyaluronan and IL-6 production by orbital fibroblasts. Mol Cell Endocrinol. 2016 433:94-104. (IF: 3.895) -> This paper illustrates the studies on novel therapies for Graves ophtalmopathy, and has led to the first treatment of a human patient with Dasatinib for Graves ophtalmopathy (unpublished results)
  • Graves; orbitopathy: the ongoing search for new treatment strategies. Dalm VASH, Paridaens D, Peeters RP. Lancet Diabetes Endocrinol. 2018 Apr;6(4):261-263. (IF:19.313) -> This invited editorial illustrates the position of the ACE in the field of novel therapies for Graves ophtalmopathy.
  • M. Medici, N. Kwong, T.E. Angell, E. Marqusee, M.I. Kim, M.C. Frates, C.B. Benson, E.S. Cibas, J.A. Barletta, J.F. Krane, D.T. Ruan, N.L. Cho, A.A. Gawande, F.D. Moore Jr, E.K. Alexander. The variable phenotype and low-risk nature of RAS-positive thyroid nodules. BMC Med. 2015 Aug 7;13:184. (IF:9.088) -> This paper illustrates our work on genetics of thyroid nodules, and was performed when one of our fellows was performing an international fellowship at Harvard Medical School. The ACE is currently leading a multicenter study on molecular markers for thyroid nodules
  • Comparing the Prognostic Value of the Eighth Edition of the American Joint Committee on Cancer/Tumor Node Metastasis Staging System Between Papillary and Follicular Thyroid Cancer. van Velsen EFS, Stegenga MT, van Kemenade FJ, Kam BLR, van Ginhoven TM, Visser WE, Peeters RP. Thyroid. 2018 Aug;28(8):976-981. (IF:7.557) -> This paper illustrates a systematic analysis of our dataset of patients with thyroid cancer that are treated within the ACE, and is the first analysis of this new staging system in a large cohort of patients with follicular thyroid cancer.
  • Thyroid State Regulates Gene Expression in Human Whole Blood. Massolt ET, Meima ME, Swagemakers SMA, Leeuwenburgh S, van den Hout-van Vroonhoven MCGM, Brigante G, Kam BLR, van der Spek PJ, van IJcken WFJ, Visser TJ, Peeters RP, Visser WE. J Clin Endocrinol Metab. 2018 Jan 1;103(1):169-178 (IF: 5,789) -> This paper illustrates our work on aimed at the identifcation of better markers of tissue thyroid state, using material from patients biobanked in the ACE.
  • Subclinical Hypothyroidism. Peeters RP. N Engl J Med. 2017 Jun 29;376(26):2556-2565 (IF: 79.258). & Hypothyroidism. Chaker L, Bianco AC, Jonklaas J, Peeters RP. Lancet. 2017 Sep 23;390(10101):1550-1562 (IF: 53.254). -> these 2 invited reviews on thyroid disease in these top journals illustrate the international position of the ACE
  • T.I. Korevaar, R. Muetzel, M. Medici, L. Chaker, V.W. Jaddoe, Y.B. de Rijke, E.A. Steegers, T.J. Visser, T. White, H. Tiemeier, R.P. Peeters. The association of maternal thyroid function during early pregnancy with offspring IQ and brain morphology at school-age: a population-based prospective cohort study. Lancet Diabetes and Endocrinology 2016 4:35-43 (IF:19.313) -> this study has led to a paradigm shift for the field, by showing for the first time that high-normal levels of thyroid hormone are equally detrimental as low levels
  • Derakhshan A, Peeters RP, Taylor PN, Bliddal S, Carty DM, Meems M, Vaidya B, Chen L, Knight BA, Ghafoor F, Popova PV, Mosso L, Oken E, Suvanto E, Hisada A, Yoshinaga J, Brown SJ, Bassols J, Auvinen J, Bramer WM, López-Bermejo A, Dayan CM, French R, Boucai L, Vafeiadi M, Grineva EN, Pop VJM, Vrijkotte TG, Chatzi L, Sunyer J, Jiménez-Zabala A, Riaño I, Rebagliato M, Lu X, Pirzada A, Männistö T, Delles C, Feldt-Rasmussen U, Alexander EK, Nelson SM, Chaker L, Pearce EN, Guxens M, Steegers EAP, Walsh JP, Korevaar TIM. Association of maternal thyroid function with birthweight: a systematic review and individual-participant data meta-analysis. Lancet Diabetes Endocrinol. 2020 Jun;8(6):501-510.
  • Consortium on Thyroid and Pregnancy—Study Group on Preterm Birth, Korevaar TIM, Derakhshan A, Taylor PN, Meima M, Chen L, Bliddal S, Carty DM, Meems M, Vaidya B, Shields B, Ghafoor F, Popova PV, Mosso L, Oken E, Suvanto E, Hisada A, Yoshinaga J, Brown SJ, Bassols J, Auvinen J, Bramer WM, López-Bermejo A, Dayan C, Boucai L, Vafeiadi M, Grineva EN, Tkachuck AS, Pop VJM, Vrijkotte TG, Guxens M, Chatzi L, Sunyer J, Jiménez-Zabala A, Riaño I, Murcia M, Lu X, Mukhtar S, Delles C, Feldt-Rasmussen U, Nelson SM, Alexander EK, Chaker L, Männistö T, Walsh JP, Pearce EN, Steegers EAP, Peeters RP. Association of Thyroid Function Test Abnormalities and Thyroid Autoimmunity With Preterm Birth: A Systematic Review and Meta-analysis. JAMA. 2019 Aug 20;322(7):632-641

PhD theses of the last five years

  • Dr. S. Groeneweg: Thyroid Hormone Transporters: from Molecules to Patients (2019)
  • Dr. D. Levie: Maternal Iodine Status, Thyroid Function During Pregnancy, and Child Neurodevelopment (2019)
  • Dr. K. Wejaphikul: Complexity of Genomic Actions Controlled by Thyroid Hormone Receptors (2019)
  • Dr. M. Barjaktarovic: Early Life Impacts of Thyroid Function and Human Chorionic Gonadotropin (hCG). (2018)
  • Dr. A.A.A. van Mullem: Clinical and molecular aspects of nuclear thyroid hormone action. (2018)
  • Drs. Beukhof: Clinical factors affecting thyroid hormone action and treatment outcome of thyroid diseases. (planned december 14th 2018)
  • Drs. Bano: Thyroid function, cardiometabolic health and general health; populationbased studies among middle-aged and older adults. (planned december 18th 2018)
  • Dr. T.I.M. Korevaar: Thyroid hormone availability during pregnancy and early life: determinants, interpretation and consequences. (2017)
  • Dr. L. Chaker: Glandula thyreoidea et senescens. (2017).
  • Dr. A. Van Gucht: Molecular and Clinical Implications of Thyroid Hormone Transport and Action. (2017)
  • Dr. E.M. Massolt: Translational studies towards understanding clinical effects of thyroid hormone. (2017)
  • Dr. S. Virakul: New Insights in the Pathogenesis of Graves' Ophthalmopathy: Potentials for targeted therapy. (2016)
  • Dr. C. Zevenbergen: Cellular mechanisms of thyroid hormone homeostasis. (2015)
  • Dr. N. Kelderman-Bolk: Intestinal absorption of thyroid hormone. (2015)
  • Dr. S. Kersseboom: Psychomotor retardation caused by mutations in MCT8: pathogenesis and therapy. (2014)
  • Dr. M. Medici: Causes and consequences of thyroid dysfunction throughout life: a population-based and genetic approach. (2014)

Non-scientific publications related to the ACE

  • A.M. Leung, T.I. Korevaar, R.P. Peeters, R.T. Zoeller, J. Köhrle, L.H. Duntas, G.A. Brent, B.A. Demeneix. Exposure to Thyroid-Disrupting Chemicals: A Transatlantic Call for Action. Thyroid. 2016 26:479-80 (IF:7,557) -> this call for action illustrates the societal and environmental activities of the ACE.
  • H. Völzke, P. Caron, L. Dahl, J.J. de Castro, I. Erlund, S. Gaberšček, I. Gunnarsdottir, A. Hubalewska-Dydejczyk, T. Ittermann, L. Ivanova, B. Karanfilski, R.M. Khattak, Z. Kusić, P. Laurberg, J.H. Lazarus, K.B. Markou, R. Moreno-Reyes, E.V. Nagy, R.P. Peeters, V. Pīrāgs, J. Podoba, M.P. Rayman, U. Rochau, U. Siebert, P.P. Smyth, B.H. Thuesen, A. Troen, L. Vila, P. Vitti, V. Zamrazil, M.B. Zimmermann. Ensuring Effective Prevention of Iodine Deficiency Disorders. Thyroid. 2016 26:189-96. 80 (IF:7.557) -> This paper from the Euthyroid consortium (in which the ACE actively participates and which aims to eliminate iodine deficiency in Europe) illustrates the involvement of the ACE with prevention and with changing international policies
  • How Do We Improve the Impact of Iodine Deficiency Disorders Prevention in Europe and Beyond? Völzke H, Erlund I, Hubalewska-Dydejczyk A, Ittermann T, Peeters RP, Rayman M, Buchberger M, Siebert U, Thuesen BH, Zimmermann MB, Grünert S, Lazarus JH. Eur Thyroid J. 2018 Aug;7(4):193-200. -> Similarly, this paper again illustrates the involvement of the ACE with prevention and with changing international policies
  • T.I. Korevaar, M. Medici, R.P. Peeters. Subclinical hypothyroidism overdiagnosis in pregnant women. JAMA Internal Medicine 2015 175:1872-3 (IF: 13,116) -> This letter illustrates the position of the ACE in the international debate on diagnosis of thyroid disease in pregnancy
  • J. Jonklaas, A.C. Bianco, A.J. Bauer, K.D. Burman, A.R. Cappola, F.S. Celi, D.S. Cooper, B.W. Kim, R.P. Peeters, M.S. Rosenthal, A.M. Sawka. Guidelines for the Treatment of Hypothyroidism, Prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement. Thyroid. 2014 24:1670-751. (IF:7.557) -> Illustrates the involvement of a member of the ACE (only non-American in this American Guideline on treatment of hypothyroidism)
  • S.H. Pearce, G. Brabant, L.H. Duntas, F. Monzani, R.P. Peeters, S. Razvi, J.L. Wemeau. 2013 ETA Guideline: Management of Subclinical Hypothyroidism. Eur Thyroid J. 2013 2:215–228 -> Illustrates the involvement of the ACE in European guidelines
  • A.C. Bianco, G. Anderson, D. Forrest, V.A. Galton, B. Gereben, B.W. Kim, P.A. Kopp, X.H. Liao, M.J. Obregon, R.P. Peeters, S. Refetoff, D. Sharlin, W.S. Simonides, R.E. Weiss, G. Williams. American Thyroid Association Guide to Investigating Thyroid Hormone Economy and Action in Rodent and Cell Models. Thyroid. 2014 24:88-168 (IF: 7.557) -> Illustrates the involvement of the ACE not only in clinical guidelines, but also in guides how to best perform scientific studies
  • L. Duntas, N. Amino, I. Hay, M. McDermott, R. Peeters, M. Vaismann, L. Ward, G. Williams, T.O. San Luis Jr, P. Yen. Thyroid disorders, noncommunicable diseases that gravely impact public health: a commentary and statement by the Advisory Board of the World Thyroid Federation. Thyroid. 2012 Jun;22(6):566-7. -> this statement from the board of the World Thyroid Federation illustrates the global position of the ACE, and its commitment to society.
  • Publications in patient related magazines/information for patients published by the ACE: - & - Schild (september 2013): Zwangerschap en schildklier, een lastige combi - Schild (Jan 2016): Schildklierfunctie in de zwangerschap en hersenontwikkeling van het kind - Nieuwe inzichten in een lang bekend verband. - Schild (juni 2017): Schildklierstimulatie tijdens de zwangerschap - Schild (Juni 2018): Een juiste instelling luistert nauw - Schildklier Organisaties Nederland, September 2014; “Hyperthyroidism and high blood pressure during pregnancy”
  • Publications/interviews in national newspapers: - Telegraaf: july 2014: Scientific appendic: Defect thyroid hormone transporters (a report and interview regarding the international Tric Trial led by the ACE) - Volkskrant 23 mei 2015: Kunnen we zo maar stoppen met brood? (an interview related to the Horizon2020 funded EUthyroid project of the ACE) - Algemeen Dagblad 11 februari 2016: Zonder brood risico op lager IQ bij je baby (an interview related to the inaugural lecture of professor Peeters) Interviews on national radio: - - -
  • Research updates on (2019: 2020 )

Principal coordinator(s)